Sponsored Links
| GTx Announces ASCO Presentations Highlighting Effects Of Ostarine™ On Physical Function And Survival In Patients With Non-Small Cell Lung Cancer |
 |
 |
 |
| Medical News - Lung Cancer | |
|
GTx, Inc. (NASDAQ: GTXI) announced today in a Phase IIb clinical trial evaluating Ostarine™ (GTx-024), a selective androgen receptor modulator, for the treatment of muscle wasting in patients with cancer, Ostarine™ treatment improved physical function and overcame the negative prognostic effect of severe weight loss on overall survival in patients with non-small cell lung cancer... Read more: Lung Cancer News From Medical News Today
|